Nkarta (NKTX) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T16:57:39.477Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:57:39.477Z.

Quote observation: 2026-10-06T16:55:05.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -122,616,000
Quote market capitalization: 169,204,772
Total debt · period ending 2026-06-30: 73,539,000
Cash · period ending 2026-06-30: 24,958,000

FMP input reference: bddae1a009f0b40e7fb659cb125a310776fd64778f9839bff19075a224db575c

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

NKTX EBITDA Yield Metrics

EBITDA YIELD

N/A

NKTX Competitors' EBITDA Yield

NKTX

Nkarta, Inc.

Current

Market Cap

$169.20M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MDWD

MediWound Ltd.

vs NKTX

Market Cap

$169.76M

EBITDA Yield

N/A

TTM Avg

16.58%

3Y Avg

16.58%

5Y Avg

16.58%

ORGO

Organogenesis Holdings Inc.

vs NKTX

Market Cap

$171.14M

EBITDA Yield

0.46%

TTM Avg

9.63%

3Y Avg

6.71%

5Y Avg

7.90%

OPRX

OptimizeRx Corp.

vs NKTX

Market Cap

$165.88M

EBITDA Yield

9.58%

TTM Avg

9.66%

3Y Avg

8.38%

5Y Avg

4.23%

DTIL

Precision BioSciences, Inc.

vs NKTX

Market Cap

$172.83M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CUE

Cue Biopharma, Inc.

vs NKTX

Market Cap

$172.49M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRQR

ProQR Therapeutics N.V.

vs NKTX

Market Cap

$173.48M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CMPX

Compass Therapeutics, Inc.

vs NKTX

Market Cap

$175.21M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

QTRX

Quanterix Corporation

vs NKTX

Market Cap

$162.75M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PEPG

PepGen Inc.

vs NKTX

Market Cap

$161.51M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Nkarta, Inc. (NKTX)	$169.20M	N/A	N/A	N/A	N/A
MediWound Ltd. (MDWD)vs ›	$169.76M	N/A	16.58%	16.58%	16.58%
Organogenesis Holdings Inc. (ORGO)vs ›	$171.14M	0.46%	9.63%	6.71%	7.90%
OptimizeRx Corp. (OPRX)vs ›	$165.88M	9.58%	9.66%	8.38%	4.23%
Precision BioSciences, Inc. (DTIL)vs ›	$172.83M	N/A	N/A	N/A	N/A
Cue Biopharma, Inc. (CUE)vs ›	$172.49M	N/A	N/A	N/A	N/A
ProQR Therapeutics N.V. (PRQR)vs ›	$173.48M	N/A	N/A	N/A	N/A
Compass Therapeutics, Inc. (CMPX)vs ›	$175.21M	N/A	N/A	N/A	N/A
Quanterix Corporation (QTRX)vs ›	$162.75M	N/A	N/A	N/A	N/A
PepGen Inc. (PEPG)vs ›	$161.51M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

NKTX EBITDA Yield Metrics

NKTX Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics